Drugs / cintredekin besudotox
Trials 11 · a red edge is where a trial was stopped
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cintredekin besudotox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00053040 ↗ |
| Known as | Cintredekina besudotox | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108583 ↗ |
| Known as | Cintredekine besudotox | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108583 ↗ |
| Known as | IL-13-PE38 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108583 ↗ |
| Known as | IL13-PE38QQR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00064779 ↗ |
| Action | Deplete | “Immunotoxins can locate tumor cells and kill them without harming normal cells.” NCT00006268 ↗ |
| Action | Inhibit | “Elongation factor 2 inhibitor” CHEMBL2108583 ↗ |
| Modality | Protein / enzyme biologic | “interleukin-13 PE38QQR immunotoxin” NCT00006268 ↗ |
| Route | Other | “receive interleukin-13 PE38QQR immunotoxin interstitially over 96 hours” NCT00006268 ↗ |
| Target | EEF2 | “Elongation factor 2 inhibitor” CHEMBL2108583 ↗ |
| Target | IL13RA2 | “Interleukin-13 receptor subunit alpha-2 binding agent” CHEMBL2108583 ↗ |